updated 6/23/2011 6:16:02 AM ET 2011-06-23T10:16:02

DUBLIN, Ireland, June 23, 2011 (GLOBE NEWSWIRE) -- Warner Chilcott plc (Nasdaq:WCRX) today announced that Dr. Mahdi Fawzi, the Company's President, Research and Development, will be leaving the Company to pursue other interests. Dr. Fawzi joined the Company in October 2009 as the head of Research and Development and has overseen the group's expansion through the 2009 acquisition of the global branded prescription pharmaceuticals business of The Procter & Gamble Company. It is expected that Dr. Fawzi will remain with the Company until the end of the year to assist with transitional matters.

The Company also announced that its Board of Directors has formed a special committee to oversee Research and Development during the transition period until Dr. Fawzi's successor is appointed. This special committee will be chaired by Dr. John King, a member of the Board of Directors of the Company since 2005. Dr. King worked for the Company's predecessors in various roles for over 26 years, and was the Executive Chairman of one of the Company's predecessors from 2000 until January 2005. He is a member of both the Pharmaceutical Society of Northern Ireland and Ireland. Dr. King earned a B.Sc., a Ph.D. degree in pharmacy and an honorary D.Sc. from Queens University of Belfast. 

"On behalf of the Company, I want to thank Dr. Fawzi for his contributions during his tenure here, and wish him success in his future endeavors. In addition, I'd like to thank Dr. King for agreeing to chair the special committee to oversee Research and Development. Given his scientific expertise and thorough understanding of the Company's products and business, I believe he is well-suited to serve in this oversight role during the transitional period," said Roger Boissonneault, Warner Chilcott's President and Chief Executive Officer.

The Company

Warner Chilcott is a leading specialty pharmaceutical company currently focused on the women's healthcare, gastroenterology, dermatology and urology segments of the North American and Western European pharmaceuticals markets. The Company is a fully integrated company with internal resources dedicated to the development, manufacturing and promotion of its products. WCRX-G

CONTACT: Emily Hill
         Investor Relations

© Copyright 2012, GlobeNewswire, Inc. All Rights Reserved


Discussion comments


Most active discussions

  1. votes comments
  2. votes comments
  3. votes comments
  4. votes comments

Data: Latest rates in the US

Home equity rates View rates in your area
Home equity type Today +/- Chart
$30K HELOC FICO 3.79%
$30K home equity loan FICO 4.99%
$75K home equity loan FICO 4.69%
Credit card rates View more rates
Card type Today +/- Last Week
Low Interest Cards 13.83%
Cash Back Cards 17.80%
Rewards Cards 17.18%
Source: Bankrate.com